NICE’s latest technology appraisal of the flu antiviral drugs (amantadine, oseltamivir and zanamivir), published in February 2009 marks the sixth time these drugs have been considered. The timelines are shown below. […]
Tag: health technology assessment
James Raftery: End of life drugs – what premium? Pt 2
Having recommended NHS use of sunitinib for renal cancer, the appraisal committee of the National Institute of Health and Clinical Excellence (NICE) issued separate draft guidance for consultation, recommending against the use of bevacizumab, sorafenib, and temsirolimus, which – along with sunitinib – had been rejected for renal cancer in 2008. […]
James Raftery: End of life drugs—what premium? Pt 1
The National Institute for Health and Clinical Excellence (NICE), the UK drugs watchdog, is currently appraising the use of four drugs—bevacizumab, sorafenib, sunitinib, and temsirolimus—for the treatment of advanced or metastatic renal cell cancer. NICE has decided to split this appraisal in two, in order to get guidance out to the NHS as quickly as […]